colm leonard

NHS Consultant Chest Physician; Honorary Professor of Respiratory Medicine; Chief Clinical Officer INFEX Therapeutics: AMR & sustainable antimicrobial pipeline

[colm leonard @LeonardColm]

@colinbrown_id @SMHopkins Very well deserved Colin. Hearty congratulations. C

[colm leonard @LeonardColm]

@INFEX_TX @AlderleyPark @Bionow #BioInfect is always a super chance to hear what’s happening in AMR space. And it was great to present data on RESP-X. An exciting year as more of the data from ph2a emerges

[colm leonard @LeonardColm]

@Bionow @INFEX_TX Thanks for the introduction. Slight typo. I was clinical lead for UK antimicrobial subscription project, which delivered a world first ‘pull incentive’ for 2 antibiotics, until I jumped into antimicrobial development role with INFEX in 2023

[colm leonard @LeonardColm]

I am biased but this is a fabulous interstitial lung disease course. Best to get registered quickly as it is usually oversubscribed

[Bavi @bavi_Kumar28]

Join as at the Manchester Interstitial Lung Diseases (MILD) 2026 on 26th/27th March @ConalHayton @LeonardColm @CristinaAvram8 @JBlaikley

Booking link below!

[colm leonard @LeonardColm]

@OSibila It is indeed a nice review article, Oriol. However, it is incomplete as it excludes RESP-X, a very long-acting monoclonal antibody targeting Pseudomonas aeruginosa. Phase 1 healthy volunteer data presented at Vienna ERS, phase 2a study just finishing with data imminent @INFEX_TX

[colm leonard @LeonardColm]

@dublin_damo Please do keep posting Damian. I left Dublin a long time ago & then photos & posts are very enjoyable, likewise those from overseas. Some great ideas for travel & food 🍱

[colm leonard @LeonardColm]

Be wary of using @FedEx for deliveries from USA to UK. My new stethoscope arrived in UK one week ago & I still have not received it. FedEx live chat & phone numbers do not allow human conversation! Appalling service

[colm leonard @LeonardColm]

@FlyLoganair You didn’t read my message. The handling agent doesn’t answer the phone & by email they say to contact Loganair!

[colm leonard @LeonardColm]

Beware flying with @FlyLoganair as my Wife experiencing terrible customer service Manchester to Aberdeen . Flew yesterday to Aberdeen, no baggage put on plane, told it would be on following flight, 2 flights later bag still in Manchester. Loganair unhelpful as is handling agent

[colm leonard @LeonardColm]

@Mike_kim714 I’ve enjoyed your insights into life on tour Michael. Wishing you even more success for rest of year & next season

[colm leonard @LeonardColm]

@dublin_damo Thanks so much for posting this journey, Damian. It has made me determined to do one of the Camino walks in the not too distant future

[colm leonard @LeonardColm]

Very excited to work with Asian ADVANCE-ID network to plan clinical trials of our novel metallo-beta-lactamase (MBL) inhibitor, MET-X. Antimicrobials targeting MBL mechanism of Gram negative bacterial resistance to antibiotics is key gap in pipeline. @davidantibiotic @INFEX_TX

[INFEX Therapeutics @INFEX_TX]

Infex agrees collaboration with Asian clinical trials network, ADVANCE-ID

Memorandum of Understanding signed to investigate hospital-acquired drug-resistant infections in Asia:
https://t.co/XGywbHjNug

[colm leonard @LeonardColm]

Excited to share our licensing deal in India for clinical development of MET-X our novel metallobetalactamase (MBL) inhibitor. MBL mechanism of resistance is an enormous problem in India & SE Asia & a rising problem EU & USA. MBL mechanism is a key pipeline priority for WHO

[INFEX Therapeutics @INFEX_TX]

Infex signs exclusive license agreement with Venus Remedies Ltd to advance MET-X through clinical development and commercialisation in India:
https://t.co/MKHz8q81k8

[colm leonard @LeonardColm]

@INFEX_TX Excited to share our licensing deal in India for clinical development of MET-X our novel metallobetalactamase (MBL) inhibitor. MBL mechanism of resistance is an enormous problem in India & SE Asia & a rising problem EU & USA. MBL mechanism is a key pipeline priority for WHO

[colm leonard @LeonardColm]

Novel pathways to combat antimicrobial resistance sorely needed. Its super that with this PACE funding INFEX & the team at Justus-Liebig-University Giessen can now advance this exciting BamA inhibitor project towards clinical trial readiness

[INFEX Therapeutics @INFEX_TX]

Infex and Justus-Liebig-University Giessen awarded £1 million grant from PACE:
https://t.co/VCxzbNPdy0

[colm leonard @LeonardColm]

@gardp_amr thanks for sharing @UKHSA reportThe doubling of reporting rates for carbapenemase-producing bugs from 4.7/100k to 10.1/100k between 2021 & 2023 is scary. One health approach, optimal stewardship of existing antibiotics & a robust pipeline of new agents urgently needed

[Global Antibiotic R&D Partnership (GARDP) @gardp_amr]

📊 New data from @UKHSA: Antibiotic-resistant infections in 2023 exceeded pre-pandemic levels

An alarming 66,730 serious cases were reported - compared to 62,314 in 2019.

👉https://t.co/jxqod3aWKl

[Global Antibiotic R&D Partnership (GARDP) @gardp_amr]

📊 New data from @UKHSA: Antibiotic-resistant infections in 2023 exceeded pre-pandemic levels

An alarming 66,730 serious cases were reported - compared to 62,314 in 2019.

👉https://t.co/jxqod3aWKl

[colm leonard @LeonardColm]

This is scary, warzone superbugs come to visit! Funders, regulators, HTA entities need to facilitate antibiotic pipeline to have necessary armoury to fight this threat. Antimicrobial resistance is not a silent threat. Antimicrobial BioTech needs support https://t.co/q4ipJ3hPEc

[colm leonard @LeonardColm]

@NICEComms @StephenJ_Fowler @BTSrespiratory @signguidelines Congratulations @StephenJ_Fowler & British Thoracic Society & @NICEComms
Fantastic collaboration to ensure fit for purpose guidelines for asthma

[colm leonard @LeonardColm]

@WeFightAMR @AmrInsights This situation cannot continue. We need the PASTEUR Act ASAP. Otherwise we face a future at the mercy of antibiotic resistant infections without an adequate armoury of effective agents